• 제목/요약/키워드: Non-cancer patient

검색결과 568건 처리시간 0.023초

Stage-Wise Presentation of Non-Metastatic Head and Neck Cancer: an Analysis of Patients from the Kumaon Hills of India

  • Pandey, Kailash Chandra;Revannasiddaiah, Swaroop;Pant, Nirdosh Kumar;Bhatt, Harish Chandra
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권12호
    • /
    • pp.4957-4961
    • /
    • 2014
  • Background: Head and neck cancer without distant metastases is amenable to various modalities of treatment. However, the stage at presentation is a very important determinant for treatment success. The present study was conducted to determine the stage-wise presentation of non-metastatic head and neck cancer patients from the hilly regions in Kumaon division of Uttarakhand, India. Materials and Methods: The hospital records for non-metastatic head and neck cancer patients from the only functional cancer centre of the region for the period of two-years (January 2012-December 2013) were included. Nasopharyngeal carcinoma was excluded due to its staging system being different. Non-squamous histopathologies were also excluded. Patients hailing from nearby regions of Uttar Pradesh and Nepal were excluded, as were patients from non-hilly regions of Kumaon. Results: Of the 271 patients of head and neck cancer, 27 with distant metastases at diagnosis were excluded from the analysis. Of the 244 eligible patient records, 90.1% (n=222) were male, and 9.9% (n=22) were female. The proportions of patients with carcinoma of the larynx, oropharynx, oral cavity, hypopharynx and maxillary antrum were 31.9% (n=78), 27.9% (n=68), 20.5% (n=50), 12.7% (n=31) and 1.2% (n=3). A further 5.7% (n=14) were diagnosed as having secondary involvement of neck nodes with unknown primaries. The proportion of patients presenting in stages I, II, III, IVA and IVB were 0.8% (n=2), 2.5% (n=6), 9.4% (n=23), 51.6% (n=126) and 35.7% (n=87) respectively. Conclusions: An abysmally low proportion (3.3%) of non-metastatic head and neck cancer patients presented in the early stages (I and II). A vast majority of the patients (88.1%) presented with stages IVA and IVB. Not only does this reflect a poor therapeutic outlook, but also exposes the dire need for programmes focusing on cancer awareness and early detection in the region.

Malignant Ascites after Subduroperitoneal Shunt in a Patient with Leptomeningeal Metastasis

  • Lee, Min-Ho;Lee, Jung-Il
    • Journal of Korean Neurosurgical Society
    • /
    • 제50권4호
    • /
    • pp.385-387
    • /
    • 2011
  • Leptomeningeal metastasis is a devastating complication of advanced stage cancer. It is frequently accompanied by hydrocephalus and intracranial hypertension that must be treated by ventriculoperitoneal shunts. However, there are actual risks of peritoneal seeding or accumulation of malignant ascites after the cerebrospinal fluid diversion procedure, though it has not been reported. Here, we present the case of a patient with non-small cell lung cancer with leptomeningeal metastasis in whom malignant ascites developed after a subduroperitoneal shunt.

Outcomes of Triple-Negative Versus Non-Triple-Negative Breast Cancers Managed with Breast-Conserving Therapy

  • Bhatti, Abu Bakar Hafeez;Khan, Amina Iqbal;Siddiqui, Neelam;Muzaffar, Nargis;Syed, Aamir Ali;Shah, Mazhar Ali;Jamshed, Arif
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권6호
    • /
    • pp.2577-2581
    • /
    • 2014
  • Background: Triple negative breast cancer is associated with aggressive behavior and high risk of local and regional failure. Aggressive surgical intervention is considered suitable. This makes role of breast conserving therapy (BCT) debatable in these patients. The objective of this study was to compare outcome of BCT for triple negative versus non-triple negative breast cancer. Materials and Methods: Medical records of patients who underwent breast conserving therapy from 1999 to 2009 at Shaukat Khanum Cancer Hospital and had complete receptor status information were extracted. Patients were divided into triple negative breast cancer (TNBC) and non-TNBC. Patient characteristics, medical treatment modalities and adverse events were compared. Expected five year locoregional recurrence free, disease free and overall survival was calculated. The Cox proportional hazard model was used to identify independent predictors of outcome. Results: A total of 194 patients with TNBC and 443 with non-TNBC were compared. Significant difference was present for age at presentation (p<0.0001), family history (p=0.005), grade (p<0.0001) and use of hormonal therapy (p<0.0001). The number of locoregional failures, distant failures and mortalities were not significantly different. No significant difference was present in 5 year locoregional recurrence free (96% vs 92%, p=0.3), disease free (75% vs 74%, p=0.7) and overall survival (78% vs 83%, p=0.2). On multivariate analysis, tumor size, nodal involvement and hormonal treatment were independent predictors of negative events. Conclusions: Breast conserving therapy has comparable outcomes for triple negative and non-triple negative breast cancers.

유전자 수송계의 현재까지의 연구동향 및 앞으로의 개발전략 (Recent Advances and Future Strategy in Gene Delivery System)

  • 최우정;김종국
    • Journal of Pharmaceutical Investigation
    • /
    • 제30권1호
    • /
    • pp.1-12
    • /
    • 2000
  • Gene therapy is a method for the treatment of diseases with introducing the gene-engineered materials into a patient with gene-deficiency disease (e.g. cystic fibrosis) or cancer to produce a therapeutic protein in a patient's cells. Successful gene therapy requires establishing both gene expression systems and delivery systems. Viral and non-viral vectors have been used for gene delivery. Viral vectors have a high transfection efficiency, but are limited in relations to issues of safety, toxicity and immunogenecity. Non-viral vectors are easy to prepare and relatively safe. However, non-viral vectors have a low transfection efficiency. Cationic liposomes are the most available among non-viral vectors. Cationic liposomes have been used to transfect cells both in vitro and in vivo experiments. Besides, several formulations containing cationic lipid are being used in clinical trials in cases of cystic fibrosis or cancer. A crucial subject to the further development of gene delivery vectors will be a long-term gene expression with following characteristics; protecting and deliverying DNA efficiently, non-toxic and non-immunogenic, and easy to produce in large scale.

  • PDF

위암수술 환자에서의 Critical Pathway의 개발과 적용 (Critical Pathway for Operable Gastric Cancer)

  • 송교영;김승남;박조현
    • Journal of Gastric Cancer
    • /
    • 제5권2호
    • /
    • pp.95-100
    • /
    • 2005
  • 목적: Critical pathway (CP)는 특정질환 표준화를 통해 적정한 진료 및 최소한의 표준진료를 행하여 진료의 질을 높이고 비용을 감소시켜 환자 및 의료진의 만족도를 높이기 위해 시도되고 있다. 본 연구는 위암수술 환자에서 CP를 개발 및 적용하고 이를 통해 치료결과의 향상을 이룰 수 있는지 알아보고자 하였다. 대상 및 방법: 2003년 10월부터 2004년 8월까지 가톨릭대학교 의과대학 강남성모병원에서 위암으로 수술 받은 185명의 환자 중 타장기 원발암이 없고, 근치적절제술을 시행 받은 환자 117예에서, CP를 적용한 26예와 동기간 동안 CP를 적용하지 않은 환자 91예의 임상적 특성, 수술 후 경과, 진료비용, 입원기간 및 환자 91예의 임상적 특성, 수술 후 경과, 진료비용, 임원기간 및 환자 만족도 등을 비교하여 위암수술에서 CP의 유용성을 알아보았다. CP를 개발하기 위하여 진료, 간호, 원무, 영양과 등이 참여하는 팀을 구성하여 외래검사 흐름도, 수술 전, 후 처방지, 경과기록 등을 표준화한 프로토콜을 작성하였다. 결과: CP환자 26명 중 1명은 십이지장 단단부 누출로, 1명은 술 후 위정체로 인한 장기 입원 및 재수술이 불가피 하여 제외되어 최종 분석된 환자는 24명이었다. 24명의 환자 중 8명에서 재원기간의 지연으로 인한 변이가 발생하였는데 6명은 환자가 자의적으로 퇴원을 거부하여 수술후 $1\∼2$일이 지연되었으며, 1명은 술 후 위정체로 2일 지연되었고, 1명은 수술 후 중환자실 입원 및 관찰기간이 필요하여 4일간 지연되어 변이율(variance rate)은 8/26 ($30.8\%$)였다. 평균 재원기간은 CPrns은 11.3일($10\∼15$일)이었고, Non-CP군은 17.5일($9\∼68$일)로 CPrns이 약 6일 짧았다(P<0.05), 술 후 평균 재원기간의 경우 CP군과 Non-CP군 각각 8.3일($7\∼12$일), 10.3일($7\~68$일)로 차이가 있으나 통계적으로 유의하지는 않았다(P>0.05). 양 군에서의 재원기간 중 총 진료비는 CP군이 평균 4,863,685원, Non-CP군이 평균 6,292,200원으로 CP군의 진료비가 낮았으나, 일당 진료비는 CP군은 430,414원, Non-CP군에서 높았음을 알 수 있었다(P<0.05). 13가지 항목의 만족도 조사에서도 CP군이 Non-CP군에 비해 높았다(P<0.05). 결론: 저자들이 개발하여 위암수술 환자에 적용한 CP 프로그램은 재원기간을 줄이고 총 진료비를 감소시킨 반면 일일 진료비의 상승과 환자 및 의료진의 만족도를 높일 수 있었다. 향후 다기관이 참여하는 전향적인 연구를 통해 보다 적절한 표준진료지침을 개발하여 그 효용성을 객관화 시켜야 할 것으로 사료된다.

  • PDF

비소세포성 폐암환자의 Crizotinib과 삼칠충초정 병용투여 경과관찰 1례 (A Case of Patient with Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Crizotinib)

  • 하수정;송시연;박소정;전형준;이연월;조종관;유화승
    • 대한암한의학회지
    • /
    • 제23권1호
    • /
    • pp.23-32
    • /
    • 2018
  • ALK 변이는 비소세포성 폐암에서 차지하는 비율은 높지 않지만 비소세포성 폐암의 발생률이 높기 때문에 환자 수는 적지 않다. ALK 저해제인 Crizotinib은 환자들의 무진행 생존을 평균 대략 4개월 정도 연장시키고 증상을 완화시키며 항암 치료를 받는 것에 비교하여 삶의 질을 향상시키는 치료성과를 거두었다. 하지만 약물 내성 발현은 주요 한계이며 여전히 ALK 변이 비소세포성 폐암 환자의 예후가 불량하므로 내성을 극복하고 지속적인 치료 반응을 유도하여 치료율을 상승시키기 위한 연구가 필요하다. 현재 폐암치료 한약제제인 삼칠충초정과 2세대 EGFR TKI 제제인 Afatinib의 동시 사용 시 상승효과가 나타난다는 연구결과는 보고되어 있지만 ALK 저해제인 Crizotinib과의 병용 치료와 관련한 연구는 시행된 바가 없었다. 본 증례는 삼칠충초정과 Crizotinib의 병용 투여를 통해 종양 크기의 불변 및 삶의 질 개선과 Crizotinib의 내성 억제 가능성 등을 보인 점에서 의의가 있으나 대조군이 없는 1례에 불과하여 Crizotinib의 단독 효과일 가능성을 배제할 수 없는 한계를 지닌다. 따라서 향후 삼칠충초정과 Crizotinib의 병용투여에 대한 추가적인 연구 및 임상시험을 통해 더욱 객관적인 효과 판정이 필요할 것으로 사료된다.

Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma

  • Wen, Ru-Min;Zhang, Yi-Jing;Ma, Sha;Xu, Ying-Li;Chen, Yan-Su;Li, Hai-Long;Bai, Jin;Zheng, Jun-Nian
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권9호
    • /
    • pp.3703-3708
    • /
    • 2015
  • Background: The neutrophil-to-lymphocyte ratio (NLR) is a strong predictor of mortality in patients with colorectal, lung, gastric cancer, pancreatic and metastatic renal cell carcinoma. We here evaluated whether preoperative NLR is an independent prognostic factor for non-metastatic renal cell carcinoma (RCC). Materials and Methods: Data from 327 patients who underwent curative or palliative nephrectomy were evaluated retrospectively. In preoperative blood routine examination, neutrophils and lymphocytes were obtained. The predictive value of NLR for non-metastatic RCC was analyzed. Results: The NLR of 327 patients was $2.72{\pm}2.25$. NLR <1.7 and NLR ${\geq}1.7$ were classified as low and high NLR groups, respectively. Chi-square test showed that the preoperative NLR was significantly correlated with the tumor size (P=0.025), but not with the histological subtype (P=0.095)and the pT stage (P=0.283). Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. Effects of NLR on OS (P=0.007) and DFS (P=0.011) were significant. To evaluate the independent prognostic significance of NLR, multivariate COX regression models were applied and identified increased NLR as an independent prognostic factor for OS (P=0.015), and DFS (P=0.019). Conclusions: Regarding patient survival, an increased NLR represented an independent risk factor, which might reflect a higher risk for severe cardiovascular and other comorbidities. An elevated blood NLR may be a biomarker of poor OS and DFS in patients with non-metastatic RCC.

A Breast Cancer Nomogram for Prediction of Non-Sentinel Node Metastasis - Validation of Fourteen Existing Models

  • Koca, Bulent;Kuru, Bekir;Ozen, Necati;Yoruker, Savas;Bek, Yuksel
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권3호
    • /
    • pp.1481-1488
    • /
    • 2014
  • Background: To avoid performing axillary lymph node dissection (ALND) for non-sentinel lymph node (SLN)-negative patients with-SLN positive axilla, nomograms for predicting the status have been developed in many centers. We created a new nomogram predicting non-SLN metastasis in SLN-positive patients with invasive breast cancer and evaluated 14 existing breast cancer models in our patient group. Materials and Methods: Two hundred and thirty seven invasive breast cancer patients with SLN metastases who underwent ALND were included in the study. Based on independent predictive factors for non-SLN metastasis identified by logistic regression analysis, we developed a new nomogram. Receiver operating characteristics (ROC) curves for the models were created and the areas under the curves (AUC) were computed. Results: In a multivariate analysis, tumor size, presence of lymphovascular invasion, extranodal extension of SLN, large size of metastatic SLN, the number of negative SLNs, and multifocality were found to be independent predictive factors for non-SLN metastasis. The AUC was found to be 0.87, and calibration was good for the present Ondokuz Mayis nomogram. Among the 14 validated models, the MSKCC, Stanford, Turkish, MD Anderson, MOU (Masaryk), Ljubljana, and DEU models yielded excellent AUC values of > 0.80. Conclusions: We present a new model to predict the likelihood of non-SLN metastasis. Each clinic should determine and use the most suitable nomogram or should create their own nomograms for the prediction of non- SLN metastasis.

Health Disparities between Black Hispanic and Black Non-Hispanic Cervical Cancer Cases in the USA

  • Khan, Hafiz Mohammad Rafiqullah;Gabbidon, Kemesha;Abdool-Ghany, Faheema;Saxena, Anshul;Gomez, Esneider;Stewart, Tiffanie Shauna-Jeanne
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권22호
    • /
    • pp.9719-9723
    • /
    • 2014
  • Background: Globally, cervical cancer is a major public health concern. Cervical cancer is the second most common cancer among women, resulting in approximately 500,000 cases per year. The purpose of this study is to compare disease characteristics between Black Hispanic (BH) and Black non-Hispanic (BNH) women in the US. Materials and Methods: We used stratified random sampling to select cervical cancer patient records from the SEER database (1973-2009). We used Chi-square and independent samples t-test to examine differences in proportions and means. Results: The sample included 2,000 cervical cancer cases of Black non-Hispanic and 91 Black Hispanic women. There were statistically significant differences between black Hispanic and black non- Hispanics in mean age at diagnosis (p<0.001), mean survival time (p<0.001), marital status (p<0.001), primary site of cancer (p<0.001); lymph node involvement (p<0.001); grading and differentiation (p<0.0001); and tumor behavior (p<0.001). Black women were more likely to develop cervical cancer and to have the highest mortality rates from the disease. Conclusions: Findings from this study show clear racial and ethnic disparities in cervical cancer incidence and prognosis that should be addressed.

Gefitinib 내성 후 Erlotinb과 한방 치료를 병행하여 호전된 뇌전이를 동반한 재발성 L858R 변이 비소세포폐암 환자 1례 (A Case Report of Recurrent L858R Mutation Non-Small-Cell Lung Cancer with Brain Metastases Treated with Erlotinib and Traditional Korean Medicine After Failure with Gefitinib)

  • 양정민;장권준;황우석
    • 대한한방내과학회지
    • /
    • 제43권5호
    • /
    • pp.838-853
    • /
    • 2022
  • Objectives: The purpose of this study is to report the case of a patient with recurrent L858R mutation non-small-cell lung cancer with brain metastases treated with erlotinib and traditional Korean medicine after gefitinib failure. Methods: The patient was treated with erlotinib beginning in November 2021, and gamma knife surgery was performed on November 8, 2021. The dose of erlotinib was 150 mg/day every four weeks. At the same time, the patient was treated with traditional Korean medicine. Tumor size and cerebral edema were measured using computed tomography and magnetic resonance imaging, respectively. Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Results: After treatment with erlotinib and traditional Korean medicine for six months, the extent of the growing nodule in the right upper lobe decreased during the first three months and remained stable for the following three months. Peritumoral edema showed an increase three months after gamma knife surgery, but partial improvement of cerebral edema was confirmed with additional traditional Korean medicine six months after gamma knife surgery. The symptoms of discomfort and physical activity gradually improved. Conclusions: This case study suggests that the combination of EGFR-TKI and traditional Korean medicine may contribute to a reduction in tumor size and cerebral edema while improving quality of life.